10
Participants
Start Date
January 31, 2011
Primary Completion Date
August 31, 2012
Study Completion Date
October 31, 2015
GRN163L in combination with trastuzumab
GRN163L will be administered in escalating dose cohorts on Day 1 of each 21-day cycle prior to trastuzumab infusion. Trastuzumab will be a administered day 1 of each 21-day cycle after GRN163L. There will be a 30 minute observation period between the end of the GRN163L infusion and the beginning of the trastuzumab infusion.
Indiana University Simon Cancer Center, Indianapolis
Collaborators (2)
Breast Cancer Research Foundation
OTHER
Geron Corporation
INDUSTRY
Indiana University
OTHER